 FLORHAM PARK, N.J., June 17, 2021 GLOBE NEWSWIRE -- PDS Biotechnology Corporation Nasdaq: PDSB PDS Biotechnology or the Company, a clinical-stage immunotherapy company developing a pipeline of novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,088,235 shares of common stock inclusive of the 794,117 shares that were sold pursuant to the underwriters full exercise of its option to purchase additional shares of common stock at a public offering price of 8.50 per share. Certain insiders, including certain members of the Companys board of directors and executive officers, purchased shares of PDS Biotech common stock in the offering. 